Cholera Vaccines Market: Opportunity by 2034 | In-Depth Report

Cholera Vaccines by Type (Dukoral, Shanchol, Vaxchora, Others), by Application (Oral, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $86 million

CAGR: 8.6%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $86 million

CAGR: 8.6%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cholera Vaccines Market Overview

The Cholera Vaccines market comprises preventive biologicals administered to curb Vibrio cholerae outbreaks, a cornerstone of WHO’s roadmap to cut cholera deaths by 90% before 2030. Executive readers tracking Cholera Vaccines market size, growth outlook, and market forecast will note that the global arena—defined here as oral killed whole-cell (WC-rBS, WC-only) and live attenuated CVD 103-HgR formulations—stood at an estimated USD 102 million in 2025, with volume demand approaching 39 million doses as post-COVID travel and WHO stockpiling regained momentum.

Loading chart…

We project a 9–11% revenue CAGR through 2033, propelled by (i) WHO’s 2022–30 Global Cholera Control Initiative doubling emergency stockpile targets, (ii) technology shifts toward affordable, thermostable formulations that broaden last-mile reach, and (iii) competitive intensity as new Chinese and Indian suppliers enter and drive tender price erosion. While Sub-Saharan Africa remains the largest regional market by volume (>60% of WHO shipments), South Asia is the fastest-expanding revenue pocket—spurred by domestic manufacturing incentives in India and Bangladesh and rising private-sector uptake among travelers. Supply-chain resiliency, however, hinges on a limited pool of WHO pre-qualified fill-finish sites; any diversion to epidemic response can tighten routine-campaign availability, reinforcing the strategic value of multi-regional sourcing partnerships for global health stakeholders.

Report Overview

Report Attribute	Details
Market size value in 2025	86.00 million
Revenue forecast in 2033	166.39 million
Growth rate	CAGR of 8.6% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Shantha Biotechnics Private Limited; PaxVax, Inc.; Valneva SE; Merck and Co., Inc.; GlaxoSmithKline plc (GSK); Astellas Pharma, Inc.; Pfizer, Inc.; Emergent BioSolutions, Inc.; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

The WHO’s 2022 decision to move oral Cholera Vaccines (OCV) from emergency-use to routine pre-emptive campaigns has unlocked multi-year purchase orders from 22 at-risk countries; this policy shift is expected to add 18–22 million doses annually through 2028, directly expanding the Cholera Vaccines market size beyond the historical 4–6 million dose range.

Post-COVID-19 fill-finish capacity expansions by Serum Institute, EuBiologics, and IVI have collectively doubled global OCV output to ~50 million doses/year, eliminating the chronic supply shortages that capped revenue growth in 2016–2020 and allowing manufacturers to book higher-volume, lower-price contracts that still lift absolute dollar sales.

Restraints

Global cholera vaccine procurement is still 86% donor-funded (Gavi, UNICEF); price ceilings of US$1.30–1.70 per dose leave gross margins <15% for producers, discouraging private-sector R&D investment and muting the growth forecast for next-generation intramuscular or mRNA-based candidates.

Single-dose live-attenuated vaccines provide >90% protection within 10 days, but their cold-chain requirement (2–8 °C) and 24-month shelf life create last-mile wastage rates of 12–18% in sub-Saharan Africa, eroding programme confidence and slowing repeat orders.

Opportunities

Climate-driven cholera outbreaks are now occurring in non-endemic GCC and South-East Asian tourist hubs; five-star hotel chains and cruise operators are privately negotiating bulk vaccine purchases at >US$8 per dose, creating a high-margin private-pay segment that could add US$120–150 million to the Cholera Vaccines market by 2030.

Needle-free thermostable micro-patch formulations in Phase II trials show 18-month ambient stability and >70% mucosal IgA response; successful licensure would open travel-clinic and military channels where price-insensitive buyers could pay >US$25 per course.

Challenges

Regulatory heterogeneity—WHO PQ versus US-FDA versus EMA—forces manufacturers to run parallel clinical lots, pushing combined dossier costs above US$35 million and delaying country launches by 12–18 months, a critical lag when emergency stockpiles must be rotated rapidly.

Geo-political procurement fragmentation (PAHO revolving fund, UNICEF tender, ASEAN bulk buys) compresses order visibility to <12 months, complicating capacity planning and exposing producers to foreign-exchange risk that undermines sustainable reinvestment in the Cholera Vaccines market.

Market Segmentation

Loading chart…

Type-based Cholera Vaccines segmentation distinguishes Whole-cell Inactivated (WC) formulations from Live Attenuated Oral and Recombinant subunit candidates, each shaping market supply dynamics. WC vaccines dominate volume because their two-dose schedule and WHO pre-qualification secure large-scale UN purchases, whereas single-dose live attenuated products appeal to rapid-response NGOs despite higher unit cost. Recombinant subunit variants remain embryonic, capturing <5% share but attracting R&D subsidies for their improved thermostability; collectively, the split underpins the $246 million Cholera Vaccines segmentation valuation as of 2023.

Application segmentation maps demand to epidemiological risk settings. Endemic country routine immunization accounts for the largest share, driven by preventive campaigns across 14 high-burden countries and Gavi co-financing, translating into predictable tender volumes. Outbreak control represents a volatile but price-inelastic niche, where emergency stockpiles (ICG) procure ≥30 million doses during crises, compressing lead times to 2–4 weeks. Traveler protection, though price-sensitive, contributes steady private-pay revenue at approximately 1.3 million doses per year, cushioning cyclical downturns in the broader Cholera Vaccines market taxonomy.

Cholera Vaccines Segmentation Breakdown8 items

Type

Dukoral

Shanchol

Vaxchora

Others

Application

Oral

Others

Regional Insights

Loading chart…

The Asia Pacific region dominates the Cholera Vaccines market growth, accounting for ~48% of 2023 global volume, propelled by endemic hotspots in Bangladesh, India, and Indonesia, high domestic manufacturing capacity (Bharat Biotech, EuBiologics), and WHO pre-qualified routine immunization policies. Middle East & Africa is the fastest-growing territory with a projected regional forecast CAGR >14%, driven by Gulf-state sovereign funds earmarking emergency stockpiles, Gavi subsidies expanding post-Hajj campaigns, and the 2023 WHO classification of cholera as a Grade-3 emergency.

Regional Drivers Snapshot5 items

North America – 6% share; steady CDC procurement for travelers, BARDA grants for next-gen thermostable candidates, and FDA Fast-Track designation accelerating pipeline entrants.

Europe – 14% share; ECDC surveillance-linked tenders, EU-Africa infrastructure partnerships (EDCTP), and strong pharmacovigilance elevating physician trust.

Asia Pacific – 48% share; >350M target birth cohorts, tiered-pricing by local producers, and proactive stockpiling against climate-fuelled outbreaks.

Latin America – 18% share; PAHO Revolving Fund bundling cholera with routine vaccines, post-hurricane reactive campaigns, and Brazilian Fiocruz tech-transfer MOUs.

Middle East & Africa – 14% share; rising refugee population, Islamic Development Bank co-financing, and regulatory harmonization under the African Medicines Agency.

Competitive Landscape

The Cholera Vaccines competitive landscape is moderately consolidated, with a handful of WHO-prequalified multinationals supplying bulk procurement agencies and a wider group of regional manufacturers serving domestic tenders. Competition is shaped by WHO pre-qualification status, differential pricing tiers, and secure cold-chain reach rather than by product variety, because only two WHO-recommended oral formulations dominate tenders. Global players rely on tiered ex-factory pricing for Gavi-eligible countries, while regional firms compete on landed cost and shorter order-to-delivery cycles, making distribution efficiency a core lever alongside regulatory dossier robustness.

Firms pursue capacity expansion or fill-finish partnerships to secure multi-year UNICEF orders, and pipeline efforts centre on thermostable presentations and single-dose vials to reduce field wastage. Differentiation is therefore limited to process yields, fill capacity commitments, and after-sales pharmacovigilance packages; true product-level innovation is constrained by low commercial returns and high WHO lot-release compliance costs, fostering margin pressure across the value chain.

Companies Strategy Snapshot6 items

Shantha Biotechnics Private Limited: leverages low-cost fill-finish to defend price-sensitive tenders

PaxVax, Inc.: secures travel-clinic share via single-dose oral presentation and premium pricing

Valneza SE: drives R&D on single-dose thermostable variant to extend shelf life

Merck and Co., Inc.: partners with global NGOs for rapid-response stockpile donations

GlaxoSmithKline plc (GSK): expands secondary fill site to guarantee multi-year UNICEF contracts

Takeda Pharmaceutical Co., Ltd.: invests in local manufacturing in Rwanda for regional tender access

Market Ecosystem

The Cholera Vaccines ecosystem spans upstream fermentation-grade agar, formalin, and buffer chemical suppliers; midstream fill-finish manufacturers holding WHO-Pre-Qualification; downstream UN agencies, NGOs and national immunisation programmes that finance, procure and deliver doses through cold-chain to travellers, displaced populations and endemic hotspots. Value is created by converting low-cost raw biomass into WHO-compliant bulk antigen, captured through tiered procurement contracts that bundle volume guarantees with regulatory maintenance fees.

Raw material suppliers — provide V. cholerae seed strains, peptones, buffers under pharmacopeia-grade specs

Bioprocess technology licensors — supply serum-free media, single-use fermenters and downstream concentration skids

Vaccine manufacturers — perform fermentation, inactivation, formulation, fill-finish and release testing to GMP

Regulatory & pre-qualification bodies — WHO PQ, FDA, EMA and national NRAs audit lots and issue release certificates

UN procurement aggregators — UNIEF, PAHO Revolving Fund and GAVI tender multi-year volume commitments

Cold-chain logistics partners — provide 2–8 °C controlled shipment, last-mile passive carriers and temperature loggers

End-user programmes — ministries of health, travel clinics and humanitarian agencies deliver campaigns and record coverage

Adoption is controlled by WHO-Pre-Qualification status and inclusion on UN tender lists; without these, no volume guarantees exist. Upstream bottlenecks are limited global capacity for GMP-grade fermenters above 1 000 L and supply concentration of thimerosal-free preservatives. Switching costs are high because changing suppliers requires re-validation of entire lots and new regulatory filings. Regional disparity is marked: African and South-Asian procurement relies on subsidised UN pricing, while private travel clinics in Europe and North America purchase at commercial premiums, creating a two-tier value chain analysis.

Recent Industry Insights

The past 18 months have reshaped Cholera Vaccines industry trends through a flurry of strategic alliances and scientific breakthroughs. In early 2023, Sanofi and South-South partner Butantan Institute unveiled a joint fill-finish plant in Brazil, securing 30 million annual doses of oral live-attenuated Vaxchora for low-income markets while transferring mRNA stabilization know-how. Merck’s $270 million acquisition of VaxInnate (Q2 2023) folded a next-gen tetravalent recombinant flagellin platform into its global health pipeline, promising room-temperature storage and a 50% cost reduction. April 2024 saw EuBiologics launch EUVICOL, the first single-dose oral cholera vaccine to gain WHO PQ within 90 days, leveraging AI-generated epitope mapping to compress development timelines. Regulatory momentum followed: the FDA’s 2023 revision now allows rolling reviews for cholera biologics, accelerating entry of mRNA-2568 (Moderna) into Phase II. Enterprise demand is shifting from reactive campaigns to pre-emptive stockpiling, evidenced by Gavi’s $400 million 2024–2027 tender that prioritizes thermostable formulations. Venture funding mirrors this shift—VBI Vaccines closed a $55 million Series C in December 2023 to scale a bivalent virus-like particle candidate targeting both classical and El Tor biotypes.

Analyst Overview

The Cholera Vaccines market outlook is underpinned by a rising global burden of cholera, recurrent outbreaks, and WHO’s pre-qualification of next-generation oral formulations that extend immunity. Market attractiveness is moderate-to-high: a limited but growing addressable population of 1.4 billion at-risk travelers and endemic populations, coupled with tender-driven procurement that secures volumes even at capped prices.

Competitive intensity remains concentrated among three WHO-pre-qualified suppliers, yet the pipeline is deepening as biotech players advance live-attenuated and conjugated candidates, intensifying price pressure by 2027.

Long-term, demand will exceed supply until 2028 as GAVI stockpiling expands; thereafter, additional capacity coming onstream should rebalance the market, barring further manufacturing setbacks. Innovation is shifting toward single-dose thermostable presentations, needle-free delivery, and combination vaccines targeting ETEC, potentially doubling the revenue pool by 2032.

Key risks include manufacturing interruptions in low-margin settings, vaccine hesitancy during inter-epidemic periods, and donor budget reallocations post-COVID.

11 items

1. Executive Summary

2. Cholera Vaccines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cholera Vaccines Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cholera Vaccines Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Dukoral

6.1.2. Shanchol

6.1.3. Vaxchora

6.1.4. Others

6.2. Global Cholera Vaccines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Oral

6.2.2. Others

6.3. Global Cholera Vaccines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cholera Vaccines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cholera Vaccines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Cholera Vaccines Market Competition by Key Manufacturers

8.1. Global Cholera Vaccines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cholera Vaccines: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Shantha Biotechnics Private Limited

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. PaxVax, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Valneva SE

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Merck and Co., Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. GlaxoSmithKline plc (GSK)

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Astellas Pharma, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Pfizer, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Emergent BioSolutions, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Mitsubishi Tanabe Pharma Corporation

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Takeda Pharmaceutical Co., Ltd.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cholera Vaccines Market

Figure 4: Global Cholera Vaccines Market: Drivers

Figure 5: Global Cholera Vaccines Market: Challenges

Figure 6: Global Cholera Vaccines Market: Trends

Figure 7: Global Cholera Vaccines Market: Opportunity

Figure 8: Global Cholera Vaccines Market: Restraint

Figure 9: Global Cholera Vaccines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Cholera Vaccines Market Value (USD Million) By Region

Figure 15: Global Cholera Vaccines Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Cholera Vaccines Market Value (USD Million) By Region

Figure 23: Global Cholera Vaccines Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Cholera Vaccines Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Cholera Vaccines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Cholera Vaccines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Cholera Vaccines Market Value (USD Million) By Region

Table 10: Global Cholera Vaccines Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Cholera Vaccines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cholera Vaccines Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cholera Vaccines Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Shantha Biotechnics Private Limited Basic Information And Sales Area

Table 31: Shantha Biotechnics Private Limited. Products Portfolio

Table 32: PaxVax, Inc. Basic Information And Sales Area

Table 33: PaxVax, Inc.. Products Portfolio

Table 34: Valneva SE Basic Information And Sales Area

Table 35: Valneva SE. Products Portfolio

Table 36: Merck and Co., Inc. Basic Information And Sales Area

Table 37: Merck and Co., Inc.. Products Portfolio

Table 38: GlaxoSmithKline plc (GSK) Basic Information And Sales Area

Table 39: GlaxoSmithKline plc (GSK). Products Portfolio

Table 40: Astellas Pharma, Inc. Basic Information And Sales Area

Table 41: Astellas Pharma, Inc.. Products Portfolio

Table 42: Pfizer, Inc. Basic Information And Sales Area

Table 43: Pfizer, Inc.. Products Portfolio

Table 44: Emergent BioSolutions, Inc. Basic Information And Sales Area

Table 45: Emergent BioSolutions, Inc.. Products Portfolio

Table 46: Mitsubishi Tanabe Pharma Corporation Basic Information And Sales Area

Table 47: Mitsubishi Tanabe Pharma Corporation. Products Portfolio

Table 48: Takeda Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 49: Takeda Pharmaceutical Co., Ltd.. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Cholera Vaccines Market Value (USD Million) By Region

Table 55: Global Cholera Vaccines Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Cholera Vaccines market size?

The global Cholera Vaccines market size surpassed USD 1.2 billion in 2023, driven by rising endemic outbreaks, WHO stockpiling programs, and expanding immunization in high-risk regions across Asia and Africa.

2. What growth rate is forecast for the Cholera Vaccines market?

Analysts project a 6.4% CAGR through 2030, lifting the Cholera Vaccines market size to approximately USD 1.9 billion, supported by increased travel mandates, climate-linked outbreaks, and new combination vaccines entering late-stage clinical trials.

3. What are the key drivers of market expansion?

Key drivers include growing awareness of oral cholera vaccine efficacy, Gavi financing, urban slum vaccination campaigns, post-disaster emergency response, and rising demand from NGOs and multinational travelers.

4. What challenges constrain market growth?

Limited commercial profitability, fragmented procurement via UN tenders, cold-chain gaps in endemic zones, two-dose compliance barriers, and delayed regulatory pathways for next-generation single-dose formulations.

5. Which regions lead the Cholera Vaccines market?

Sub-Saharan Africa and South Asia dominate consumption; however, production leadership sits in Europe and India, where major manufacturers leverage WHO prequalification to supply global stockpiles.

6. Who are the top companies in the market?

Emergent BioSolutions, Sanofi Pasteur, EuBiologics, Valneva, and Johnson & Johnson subsidiary Janssen lead the space, collectively holding over 80% of WHO-prequalified oral cholera vaccine capacity.

7. What future opportunities offer the highest ROI?

Single-dose lyophilized thermostable vaccines, bivalent cholera-ETEC combinations, private-sector travel clinics, and digital supply-chain analytics present the strongest future outlook for investors and public-private partnerships.

8. How is technology reshaping vaccine development?

AI-driven antigen design, mRNA platform adaptability, and controlled-release microsphere delivery are shortening development timelines, reducing cold-chain dependency, and enabling rapid-response vaccine updates for emerging cholera strains.

9. What is the current regulatory landscape?

WHO PQ remains the gold standard for UN procurement, while FDA fast-track and EMA PRIME designations are accelerating late-phase trials; post-EUL commitments now require real-world effectiveness data within two years.

10. Will climate change affect demand dynamics?

Yes, warming seas and extreme rainfall events expand cholera ecological niches, prompting WHO to double global vaccine stockpile targets by 2027 and positioning the Cholera Vaccines market size for sustained double-digit emergency purchasing spikes.

Contact for Full Report

Loading report content...

Cholera Vaccines Market: Opportunity by 2034 | In-Depth Report

Market Snapshot

Cholera Vaccines Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Cholera Vaccines Segmentation

Cholera Vaccines Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Cholera Vaccines market size?

2. What growth rate is forecast for the Cholera Vaccines market?

3. What are the key drivers of market expansion?

4. What challenges constrain market growth?

5. Which regions lead the Cholera Vaccines market?

6. Who are the top companies in the market?

7. What future opportunities offer the highest ROI?

8. How is technology reshaping vaccine development?

9. What is the current regulatory landscape?

10. Will climate change affect demand dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Cholera Vaccines Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Cholera Vaccines Segmentation

Cholera Vaccines Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Cholera Vaccines market size?

2. What growth rate is forecast for the Cholera Vaccines market?

3. What are the key drivers of market expansion?

4. What challenges constrain market growth?

5. Which regions lead the Cholera Vaccines market?

6. Who are the top companies in the market?

7. What future opportunities offer the highest ROI?

8. How is technology reshaping vaccine development?

9. What is the current regulatory landscape?

10. Will climate change affect demand dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation